Deborah Thomas

2.1k total citations
19 papers, 1.3k citations indexed

About

Deborah Thomas is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Deborah Thomas has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Public Health, Environmental and Occupational Health and 7 papers in Molecular Biology. Recurrent topics in Deborah Thomas's work include Acute Lymphoblastic Leukemia research (9 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Deborah Thomas is often cited by papers focused on Acute Lymphoblastic Leukemia research (9 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Deborah Thomas collaborates with scholars based in United States, Slovakia and Peru. Deborah Thomas's co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Guillermo Garcia‐Manero, William G. Wierda, Stefan Faderl, Alessandra Ferrajoli, Elias Jabbour and Jeffrey L. Jorgensen and has published in prestigious journals such as Chemical Reviews, Journal of Clinical Oncology and Blood.

In The Last Decade

Deborah Thomas

19 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Thomas United States 13 997 760 453 373 288 19 1.3k
Tamara Intermesoli Italy 17 575 0.6× 460 0.6× 331 0.7× 116 0.3× 214 0.7× 46 1.0k
Loredana Elia Italy 18 1.1k 1.1× 1.3k 1.6× 263 0.6× 88 0.2× 466 1.6× 35 1.6k
Nathalie Grardel France 15 848 0.9× 281 0.4× 591 1.3× 250 0.7× 160 0.6× 40 1.3k
Rebecca Garris United States 19 1.4k 1.4× 1.8k 2.4× 358 0.8× 133 0.4× 922 3.2× 103 2.1k
RE Sobol United States 11 681 0.7× 699 0.9× 296 0.7× 65 0.2× 202 0.7× 15 1.1k
HM Kantarjian United States 10 545 0.5× 233 0.3× 446 1.0× 163 0.4× 146 0.5× 12 842
Naval Daver United States 16 1.2k 1.2× 546 0.7× 372 0.8× 62 0.2× 348 1.2× 144 1.5k
M. Brigid Bradley‐Garelik United States 15 2.2k 2.2× 310 0.4× 1.9k 4.1× 1.2k 3.3× 351 1.2× 28 2.5k
G. Borthakur United States 11 681 0.7× 147 0.2× 482 1.1× 283 0.8× 127 0.4× 36 954
Monica Kwari United States 16 1.2k 1.2× 896 1.2× 433 1.0× 27 0.1× 567 2.0× 47 1.7k

Countries citing papers authored by Deborah Thomas

Since Specialization
Citations

This map shows the geographic impact of Deborah Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Thomas more than expected).

Fields of papers citing papers by Deborah Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Thomas. The network helps show where Deborah Thomas may publish in the future.

Co-authorship network of co-authors of Deborah Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Thomas. A scholar is included among the top collaborators of Deborah Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Thomas. Deborah Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Nguyen, Long C., Dongbo Yang, Deborah Thomas, et al.. (2024). Direct inhibition of tumor hypoxia response with synthetic transcriptional repressors. Nature Chemical Biology. 21(2). 247–255. 3 indexed citations
2.
Swenson, Colin, et al.. (2024). Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics. Chemical Reviews. 124(22). 13020–13093. 13 indexed citations
3.
Speltz, Thomas E., Colin Swenson, Xianghang Shangguan, et al.. (2022). Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains. Nature Biotechnology. 41(4). 541–551. 19 indexed citations
4.
Thomas, Deborah, et al.. (2021). Solvatochromic and pH-Sensitive Fluorescent Membrane Probes for Imaging of Live Cells. ACS Chemical Neuroscience. 12(4). 719–734. 13 indexed citations
5.
Thomas, Deborah, et al.. (2021). Measuring Membrane Lipid Turnover with the pH-sensitive Fluorescent Lipid Analog ND6. Journal of Visualized Experiments. 1 indexed citations
6.
Jain, Nitin, Susan O’Brien, Farhad Ravandi, et al.. (2016). Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 127(15). 1863–1869. 218 indexed citations
7.
Ravandi, Farhad, Susan O’Brien, Jörge E. Cortes, et al.. (2015). Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Cancer. 121(23). 4158–4164. 156 indexed citations
8.
Jain, Preetesh, Hagop M. Kantarjian, Deborah Thomas, et al.. (2013). Phase II Study of Nelarabine With Hyper-CVAD in Patients With Previously Untreated T cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). Clinical Lymphoma Myeloma & Leukemia. 13. S368–S369. 4 indexed citations
9.
Cassier, Philippe A., Silvia Stacchiotti, Hans Gelderblom, et al.. (2010). Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).. Journal of Clinical Oncology. 28(15_suppl). 10012–10012. 3 indexed citations
10.
Ravandi, Farhad, Susan O’Brien, Deborah Thomas, et al.. (2010). First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. Blood. 116(12). 2070–2077. 244 indexed citations
11.
Quintás‐Cardama, Alfonso, Hagop M. Kantarjian, Farhad Ravandi, et al.. (2009). Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 115(11). 2482–2490. 110 indexed citations
12.
Jones, Dan, Deborah Thomas, C. Cameron Yin, et al.. (2008). Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors. Cancer. 113(5). 985–994. 96 indexed citations
13.
Ravandi, Farhad, Deborah Thomas, Hagop Kantarjian, et al.. (2008). Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood. 112(11). 2921–2921. 5 indexed citations
14.
O’Brien, Susan, Deborah Thomas, Farhad Ravandi, et al.. (2008). Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 113(11). 3186–3191. 110 indexed citations
15.
Jones, Dan, Rajyalakshmi Luthra, Jörge E. Cortes, et al.. (2008). BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome–positive leukemias. Blood. 112(13). 5190–5192. 28 indexed citations
16.
El-Zimaity, Maha, Hagop M. Kantarjian, Moshe Talpaz, et al.. (2004). Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. British Journal of Haematology. 125(2). 187–195. 74 indexed citations
17.
Cortes, Jörge E., Patricia Ault, Charles Koller, et al.. (2003). Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 101(12). 4714–4716. 115 indexed citations
18.
19.
Thomas, Deborah, et al.. (1976). Study of cytosine arabinoside (NSC-63878) synchronization plus vincristine (NSC-67574), prednisone (NSC-10023), and L-asparaginase (NSC-109229) for remission induction in advanced acute leukemia in children.. PubMed. 60(5). 591–4. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamara Intermesoli Breakdown of academic impact, for papers by Loredana Elia Breakdown of academic impact, for papers by Nathalie Grardel Breakdown of academic impact, for papers by Rebecca Garris Breakdown of academic impact, for papers by RE Sobol Breakdown of academic impact, for papers by HM Kantarjian Breakdown of academic impact, for papers by Naval Daver Breakdown of academic impact, for papers by M. Brigid Bradley‐Garelik Breakdown of academic impact, for papers by G. Borthakur Breakdown of academic impact, for papers by Monica Kwari
Rankless by CCL
2026